IFNG gene signature overexpression
|
Lymphoma
|
IFNG gene signature overexpression
|
Lymphoma
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
IFNG gene signature overexpression
|
Head and Neck Cancer
|
IFNG gene signature overexpression
|
Head and Neck Cancer
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
IFNG gene signature overexpression
|
Cervical Cancer
|
IFNG gene signature overexpression
|
Cervical Cancer
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
IFNG gene signature overexpression
|
Urothelial Cancer
|
IFNG gene signature overexpression
|
Urothelial Cancer
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
IFNG gene signature overexpression
|
Melanoma
|
IFNG gene signature overexpression
|
Melanoma
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
IFNG gene signature overexpression
|
Pancreatic Cancer
|
IFNG gene signature overexpression
|
Pancreatic Cancer
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
IFNG gene signature overexpression
|
RCC
|
IFNG gene signature overexpression
|
RCC
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
IFNG gene signature overexpression
|
Melanoma
|
IFNG gene signature overexpression
|
Melanoma
|
nivolumab + 4SC-202 Sensitive: C3 – Early Trials
|
nivolumab + 4SC-202 Sensitive: C3 – Early Trials
|